- Home
- TBHC vs SNTI Comparison
TBHC vs SNTI Comparison
Compare TBHC & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TBHC | SNTI |
|---|---|---|
| Founded | 1966 | 2016 |
| Country | United States | United States |
| Employees | 4010 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 24.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TBHC | SNTI |
|---|---|---|
| Price | $0.92 | $0.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 71.7K | ★ 95.5K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.86 | $0.77 |
| 52 Week High | $2.40 | $5.10 |
Technical Indicators
Market Signals| Indicator | TBHC | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 42.69 | 54.48 |
| Support Level | N/A | $0.78 |
| Resistance Level | $1.27 | $0.93 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 47.00 | 99.88 |
Price Performance
Historical ComparisonAbout TBHC The Brand House Collective Inc.
The Brand House Collective Inc is a specialty retailer of home decor and gifts in the United States. The company stores provide various merchandise, including holiday decor, value pricing, and a stimulating in-store and online environment that provides customers with a brand experience. The company stores also offer an assortment of holiday merchandise in seasonal periods, as well as items that are suitable for gift-giving.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.